论文部分内容阅读
目的探讨糖化血红蛋白(HbAlc)水平对2型糖尿病微血管病变患者的评估价值。方法对45例2型糖尿病微血管病变患者、41例无微血管病变患者及42例正常对照患者分别检测HbAlc及空腹血糖(FBG)水平。结果微血管病变组HbAlc、FBG与无微血管病变组、正常对照组比较,差异有统计学意义(P<0.05或P<0.01);无微血管病变组HbAlc、FBG与正常对照组比较,差异无统计学意义(P<0.05)。结论 HbAlc检测有助于判定糖尿病微血管病变的发生、发展,提高对糖尿病肾病的预防和早期诊断。
Objective To investigate the value of HbAlc in the evaluation of patients with type 2 diabetic microangiopathy. Methods The levels of HbA1c and fasting blood glucose (FBG) were measured in 45 patients with type 2 diabetic microangiopathy, 41 patients without microvascular disease and 42 normal controls. Results There was significant difference between HbA1c, FBG and non-microangiopathy group and normal control group in microvascular disease group (P <0.05 or P <0.01). There was no significant difference between HbA1c and FBG group in non-microangiopathy group and normal control group Significance (P <0.05). Conclusion HbAlc test can help determine the occurrence and development of diabetic microangiopathy and improve the prevention and early diagnosis of diabetic nephropathy.